You are here: Industry Insights > PureTech

News List

PureTech launches phase II ‘long COVID’ drug trial pharmatimes
December 08, 2020
PureTech has initiated a phase II trial of its investigational drug candidate LYT-100 in long COVID characterised by respiratory complications and related sequelae.
PureTech advances experimental COVID-19 drug into global trials pharmatimes
May 29, 2020
UK clinical-stage biotherapeutics group PureTech has unveiled plans to advance its wholly-owned clinical-stage product candidate LYT-100 (deupirfenidone) as a potential treatment for serious respiratory complications ...
First patient dosed in potential lymphoedema treatment trial pharmatimes
March 06, 2020
PureTech has announced that the first participant has been dosed in a clinical study of LYT-100, the company’s product candidate for the potential treatment of lymphoedema and other fibrotic conditions.
Boehringer partners PureTech to develop immuno-oncology candidates pharmaceutical-technology
April 24, 2019
Boehringer partners PureTech to develop immuno-oncology candidates.
PureTech’s Vedanta raises $27m for microbiome research pharmaphorum
December 25, 2018
US-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several indications, including cancer and food allergy.
PureTech affiliate Karuna advances schizophrenia candidate pharmatimes
October 19, 2018
Karuna Pharmaceuticals, an affiliate of UK-listed biopharma PureTech Health, has kicked off a Phase II study of KarXT, which is being developed for the treatment of psychosis in schizophrenia.
PureTech Health Announces Collaboration with Roche americanpharmaceuticalreview
July 24, 2018
PureTech Health has entered into a multiyear collaboration with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.,
PureTech lifted by news of Roche deal pharmatimes
July 23, 2018
Shares in UK-based clinical-stage biopharm PureTech Health have been given a boost by news that Roche has signed up to advance its exosome platform technology in a deal potentially worth more than $1 billion.